companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

PICTOU COUNTY LOCK & ALARM

NEW GLASGOW-Canada

Company Name:
Corporate Name:
PICTOU COUNTY LOCK & ALARM
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: Westville Rd,NEW GLASGOW,NS,Canada 
ZIP Code:
Postal Code:
B2H 
Telephone Number: 9027521352 
Fax Number:  
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
129370 
USA SIC Description:
KEYS 
Number of Employees:
 
Sales Amount:
$1 to 2.5 million 
Credit History:
Credit Report:
Excellent 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
PICTOU COUNTY PERSONS SOCIETY
PICTOU COUNTY PETS
PICTOU COUNTY LOCK & ALARM
Next company profile:
PICTOU COUNTY INJURED WORKERS ASSOCIA
PICTOU COUNTY LET ABILITIES
PICTOU COUNTY LOCK & ALARM










Company News:
  • Johnson Johnsons dual-targeting CAR T-cell therapy shows encouraging . . .
    Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19 CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R R LBCL) who have not been previously treated with CAR T-cell therapy
  • Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy - Medscape
    KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly refractory large B-cell lymphoma, new research shows
  • J J lymphoma CAR-T hits 100% ORR in 10 patients - fiercebiotech. com
    Johnson and Johnson is providing a first look at clinical data for its dual-targeting blood cancer CAR-T program In a phase 1b trial of patients with relapsed or refractory large B-cell lymphoma
  • Yescarta for Relapsed or Refractory Large B-Cell Lymphoma
    CAR T-cell therapy, a type of personalized immunotherapy, can help cure some people with aggressive non-Hodgkin lymphoma (NHL) That’s according to updated results from a large randomized phase 3 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) Most people diagnosed with diffuse large B-cell lymphoma, the most common form of aggressive NHL, will be cured by
  • Johnson Johnson Reports Promising Dual CAR-T Cell Therapy Data of . . .
    In a breakthrough for oncology, Johnson Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, JNJ-90014496 (also referred to as JNJ-4496) The treatment has been demonstrated to have a strong success rate for treating patients who have relapsed or are refractory to large B-cell lymphoma (R R LBCL), a particularly aggressive
  • Trial of cell-based therapy for high-risk lymphoma leads to FDA . . .
    The researchers collected immune cells called T cells from 38 patients with large B-cell lymphoma whose cancers had started growing after previous therapies including chemotherapy All but one of the patients had also progressed after CAR-T therapy targeting CD19; the cancer cells of the one remaining patient did not express CD19 on their surfaces
  • Efficacy and safety of a novel CD19, CD22 dual-targeted fully human . . .
    Chimeric antigen receptor (CAR) T-cell therapy represents one of the most significant breakthroughs in treating relapsed or refractory B cell malignancies [1,2,3,4,5,6,7] To date, six CD19-targeted CAR-T products have been approved by the U S Food and Drug Administration (FDA) or the National Medical Products Administration (NMPA) for the treatment of relapsed refractory B cell non-Hodgkin
  • Long-term outcomes following CAR T cell therapy: what we know so far
    Long-lasting B cell depletion following CD19-targeted CAR T cell therapy is a common occurrence, with data from long-term follow-up studies indicating persistent B cell depletion in 25–38% of
  • KITE-363 Elicits Responses With Acceptable Tolerability in R R B-Cell . . .
    The anti-CD19 CD20 CAR T-cell therapy KITE-363 showcased high response rates with a manageable safety profile in patients with relapsed refractory B-cell lymphoma, according to results from a
  • Armored CAR T Cells Highly Active in Lymphoma After Prior CAR-T . . .
    New England Journal of Medicine Source Reference: Svoboda J, et al "Enhanced CAR T-cell therapy for lymphoma after previous failure" N Engl J Med 2025; DOI: 10 1056 NEJMoa2408771




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer